Abstract
The identification of target antigens in membranous nephropathy has accelerated since the report of M-type phospholipase A2 receptor 1 (PLA2R1). One could say that technological advances have allowed for the demonstration of Moore's law (a doubling every 2 years in the number of transistors that can be fit onto a computer chip) in the field of membranous nephropathy, and that even more antigens can be expected in the near future. In this issue of Kidney International, Sethi etal. describe semaphorin-3B as a novel target antigen, defining a type of membranous nephropathy with onset in the pediatric population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have